Mycophenolate-Associated Bronchiectasis
- 25 April 2014
- journal article
- letter
- Published by S. Karger AG in Respiration
- Vol. 88 (1) , 86
Abstract
Brill et al. [1] report on the potential utility of mycophenolate mofetil (MMF) as a steroid-sparing agent in chronic pulmonary sarcoidosis in 10 patients with some success in the reduction of systemic steroids while preserving lung function and clinical stability. Although this provides a welcome possible alternative to other steroid-sparing agents that might have more adverse events, such as methotrexate or azathioprine, MMF has been more recently associated [2,3] with the development of bronchiectasis (in addition to its well-known problems of gastrointestinal disturbance and leucopenia).Keywords
This publication has 3 references indexed in Scilit:
- Effect and Safety of Mycophenolate Mofetil in Chronic Pulmonary Sarcoidosis: A Retrospective StudyRespiration, 2012
- Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil‐treated renal transplant recipients: an emerging clinical phenomenon?Clinical Transplantation, 2011
- Mycophenolate Mofetil and Bronchiectasis in Kidney Transplant Patients: A Possible RelationshipTransplantation, 2006